Sara Ballabio

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites.

Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 24, 2024

Long-read sequencing reveals chromothripsis in a molecularly unsolved case of Cornelia de Lange syndrome.

Long-read sequencing reveals chromothripsis in a molecularly unsolved case of Cornelia de Lange syndrome.

Journal: Frontiers in genetics

Published: December 19, 2023

Corrigendum to "Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma" [Genomics Volume 113, Issue 5, September 2021, Pages 3439-3448].

Corrigendum to "Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma" [Genomics Volume 113, Issue 5, September 2021, Pages 3439-3448].

Journal: Genomics

Published: September 18, 2021

Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.

Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.

Journal: Genomics

Published: May 03, 2021

Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 04, 2020

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Journal: British journal of cancer

Published: February 13, 2020

Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.

Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.

Journal: International journal of cancer

Published: September 10, 2019

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 28, 2019

Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.

Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.

Journal: International journal of cancer

Published: January 14, 2019

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Journal: British journal of cancer

Published: November 09, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026